Eli Lilly and Company Stock News

Bridgewater Associates slashed a stake in Apple, halved its Lilly investment, doubled down on Microsoft, and bought Moderna in the second quarter.

AbbVie has proved it can adapt to a fast-changing environment. Eli Lilly has a sustainable culture of growth.

Eli Lilly said on Friday the U.S. Food and Drug Administration approved its eczema drug for use in adults and children above 12 years old.

EBGLYSS provides a new first-line biologic treatment for moderate-to-severe atopic dermatitis that is not well controlled with topicals Patients treated with EBGLYSS experienced significant skin clearance as early as four weeks and meaningful itch relief as early as two weeks EBGLYSS delivers long-lasting efficacy for patients through one year of treatment with a monthly maintenance dose INDIAN...

Citi has resumed coverage of Eli Lilly & Co. (NYSE: LLY) with a “Buy” rating, setting a price target of $1,060 per share—implying a potential 13% upside from the current stock price.

The pharma giant's financial results have been strong, largely thanks to its new crown jewel. But there may be more to come as the company's development pipeline looks incredibly exciting.

Eli Lilly (LLY) said Thursday it will spend $1.8 billion to expand production in Ireland of its popular diabetes and weight-loss drugs, as well as some active ingredients used in its Alzheimer's treatment Kisunla, which recently was approved in the U.S.

Money has poured into the sector as markets have grown concerned about the economy.